A view of the Novo Nordsk logo at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little Reuters
Copenhagen, Denmark – Novo Nordsk She defended the results of disappointing experiments for the next generation of the next generation CAGRISEMA, insisting that it will be an “important” treatment for weight loss.
On Thursday, CEO Lars Fergard Yorgensen admitted the reaction of sharp arrow prices after two consecutive experiences in the late stage showed an worrying weight reduction against the company's private goals, but he said that he was “shadow” encouraging “by losing drug weight.
“I am very confident about Cagrisema,” he told the shareholders at the company's annual meeting in Copenhagen, Denmark.
“It will be an important product for us.”
CAGRISEMA is a mixture of declaring dandruff – an emerging form of weighing loss known as analog amylene – and gmuutide, the active ingredient in Wegovy.
Address results from the RideFine-2 experience late in the stage Absolute Earlier this month, it showed that the complexities of complications helped adult patients with obese or overweight overweight with type 2 diabetes, 15.7 % of their weight over 68 weeks, compared to 3.1 % with the placebo. This was less than the high -loss percentage of weight loss.
Previous trial late in the stage Published In December, it showed that the drug helped patients with obese or overweight with one or more accompanying patients, but not type 2 diabetes, their weight reduces 22.7 % after 68 weeks, or less than 25 % expected.
Both the two results have wiped a great value from the price of the Novo share as the hope of investors to find a superior alternative to the current Wegovy injection and competition Elie Lily Zepbound, both GLP-1, have been resolved. The beloved inventory decreased once over 50 % of its highest levels in 2024.
Novo Nordsk
The Danish medicine giant faced again on Thursday, as the shareholders urged the board of directors to experience and more clear and sound goals in an attempt to stir less dramatic price movements.
Fruergaard jditionsen acknowledged criticism, especially about the company's failure to accurately connect flexible experiences, which raised questions about endurance, with less than two thirds of patients to the top of the dose after 68 weeks.
“22.7 % is not 25 %, so some people were disappointed about it,” he said, however, adding that the company believes that “there are” continuous potentials to develop more myself, including by extending the experimental period and the comprehensive dose.
The CEO said that Novo Nordisk is now conducting a new experience for the third stage, which is called RideFine 11, which “will explore the capabilities of Kejema.”
This comes because the weight loss industry is still divided into the broader applications and the results of obesity medications exceeding the total weight. In a note earlier this month, Bofa Global Research said it has grown “a little more cautious about differentiation” in the treatment of obesity and diabetes after the latest Cagrisema results.
However, Soren Lontoft, Pharma stock analyst in Sydbank, He said CNBC last week was needed a variety of treatments to treat both obesity and endurance levels, as well as health risks associated with cardiovascular disease, sleep breathing and liver disease.
“It is clear that there is a very big opportunity in the market, but it also requires a group of products that meet the needs of different patients,” pointed out Fruergaard J Pruteensen.
